Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

655.01 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 173
Open 655.01
Bid (Size) 657.00 (2)
Ask (Size) 689.00 (1)
Prev. Close 655.01
Today's Range 655.01 - 655.01
52wk Range 492.13 - 747.42
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Regeneron Pharmaceuticals Earnings Perspective: Return On Capital Employed
Pulled from Benzinga Pro data, Regeneron Pharmaceuticals (NASDAQ:REGN) posted Q1 earnings of $973.50 million, an increase from Q4 of 56.33%. Sales dropped to $2.96 billion, a 40.13% decrease between... 
Via Benzinga
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
Via Talk Markets

Performance

YTD
+4.45%
+4.45%
1 Month
-9.43%
-9.43%
3 Month
+5.05%
+5.05%
6 Month
+1.12%
+1.12%
1 Year
+25.07%
+25.07%

More News

Read More
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
Via Investor's Business Daily
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
Via Investor's Business Daily
$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much
Via Benzinga
How Regeneron Pharmaceuticals Beat Quarterly Projections Without Leaning On Covid
Via Investor's Business Daily
Here's Why This Analyst Cut Price Target On Regeneron
Via Benzinga
Stock Market Jumps, Then Dives After Fed Rate Hikes As Treasury Yields Soar: Weekly Review
Via Investor's Business Daily
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Regeneron Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Earnings Preview: Regeneron Pharmaceuticals
Via Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Via Benzinga
If You Invested $100 In Regeneron Pharmaceuticals 10 Years Ago, Here's How Much You Would Have Today
Via Benzinga
Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?
Via InvestorPlace
54 Biggest Movers From Yesterday
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu
Via Benzinga
Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal
Via Benzinga
Why Checkmate Pharmaceuticals Shares Are Skyrocketing
Via Benzinga
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Via Benzinga
NASDAQ: REGN Shareholder Notice: Investigation over Possible Securities Laws Violations by Regeneron Pharmaceuticals, Inc.
Via SBWire
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.